北京商报讯（记者 王寅浩 宋雨盈）1月12日，药明康德发布2025年度业绩预增公告，公司预计2025年实 现营业收入约454.56亿元，同比增长约15.84%；实现经调整归母净利润约149.57亿元，同比增长约 41.33%；实现归属于公司股东的净利润约191.51亿元，同比增长约102.65%。 ...

附："2025中国企业ESG百强"榜 新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点 击查看【 ESG评级中心服务手册】 在全球可持续发展浪潮席卷而来的当下，ESG（环境、社会、公司治理）已成为衡量企业高质量发展的核心标尺，更是连接企业价值与社会价值的关键纽 带。随着国内ESG生态体系的加速完善，政策监管持续收紧、资本市场对ESG表现的关注度不断飙升，企业的可持续发展能力愈发成为其核心竞争力的重 要组成部分。 在此行业背景下，新浪财经重磅发布"2025中国企业ESG百强"榜单。该榜单依托新浪财经专业的ESG评级体系，以5000余家A股上市公司及在港上市内地 企业为评价对象，创新性搭建18套行业ESG评价模型，纳入150余项ESG指标，通过量化模型综合演算，对企业ESG表现进行全面、客观的综合评价，最 终筛选出中国ESG实践的标杆企业。榜单不仅为行业树立了发展典范，更为投资者提供了极具参考价值的决策依据。 药明康德在环境、社会、公司治理领域开展了大量工作，积累了丰富的创新实践与扎实的落地成果。凭借在ESG各领域的卓越表现，药 ...

Core Viewpoint - WuXi AppTec (603259.SH) expects to achieve a net profit attributable to shareholders of approximately RMB 19.151 billion in 2025, representing a year-on-year growth of about 102.65% [1] Group 1: Business Model and Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing Organization) business model [1] - WuXi AppTec is committed to meeting customer demands for empowerment and is continuously expanding new capabilities and building new production capacity [1] - The company is dedicated to optimizing production processes and improving operational efficiency to drive steady business growth [1] Group 2: Commitment to Clients and Market Impact - WuXi AppTec aims to empower clients effectively and is committed to bringing more new and effective drugs to global patients [1]

Core Viewpoint - WuXi AppTec (603259.SH) expects to achieve a net profit attributable to shareholders of approximately RMB 19.151 billion in 2025, representing a year-on-year growth of about 102.65% [1] Group 1: Business Model and Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing Organization) business model [1] - It is committed to meeting customer demands for empowerment and is continuously expanding new capabilities and building new production capacity [1] - The company aims to optimize production processes and improve operational efficiency to drive steady business growth [1] Group 2: Commitment to Clients and Market - WuXi AppTec is dedicated to empowering clients efficiently and aims to bring more new and effective drugs to patients worldwide [1]

Group 1 - The company expects a revenue increase of approximately 15.84% for the fiscal year ending December 31, 2025, with projected revenue of about RMB 45,456.17 million [1] - The adjusted net profit attributable to shareholders is anticipated to be around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1] - The net profit attributable to shareholders is projected to reach approximately RMB 19.151 billion, representing a significant year-on-year increase of about 102.65% [1] Group 2 - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, enhancing capabilities and optimizing production processes to drive steady growth [2] - Non-recurring profit items impacting net profit include expected net gains of approximately RMB 4.161 billion from the sale of part of its stake in WuXi XDC Cayman Inc. and about RMB 1.434 billion from the sale of 100% stakes in two clinical research companies [2]

Core Viewpoint - WuXi AppTec (02359.HK) expects to achieve a revenue of approximately RMB 45.456 billion for the fiscal year ending December 31, 2025, representing a year-on-year growth of about 15.84% [1] Financial Performance - The revenue from continuing operations is expected to grow by approximately 21.40% year-on-year [1] - The adjusted net profit attributable to shareholders is projected to be around RMB 14.957 billion, reflecting a year-on-year increase of approximately 41.33% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be about RMB 13.241 billion, with a year-on-year growth of approximately 32.56% [1] - The total net profit attributable to shareholders is anticipated to reach approximately RMB 19.151 billion, indicating a year-on-year increase of about 102.65% [1] - The basic earnings per share are expected to be around RMB 6.70, representing a year-on-year growth of approximately 104.27% [1] Business Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model [1] - WuXi AppTec aims to meet customer demands for empowerment, continuously expanding new capabilities and building new production capacity [1] - The company is committed to optimizing production processes and improving operational efficiency to drive steady business growth and effectively empower clients [1] Non-Recurring Gains - The impact of non-recurring gains on net profit attributable to shareholders primarily comes from the net gain from the sale of part of its stake in WuXi XDC Cayman Inc., estimated at approximately RMB 4.161 billion [2] - Additionally, the net gain from the sale of 100% equity in Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. is expected to be around RMB 1.434 billion [2]

证券代码：603259 证券简称：药明康德 公告编号：临 2026-002 无锡药明康德新药开发股份有限公司 2025 年度业绩预增公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）持 续聚焦独特的"一体化、端到端"CRDMO（合同研究、开发与生产）业务模式， 紧抓客户对赋能需求的确定性，不断拓展新能力、建设新产能，持续优化生产工 艺和提高经营效率，推动业务持续稳健增长，高效极致赋能客户并致力于将更多 新药、好药带给全球病患。 1、公司预计 2025 年度（以下简称"本期"）实现营业收入约人民币 4,545,617 万元，同比增长约 15.84%，其中持续经营业务收入同比增长约 21.40%。 2、公司预计本期实现经调整非《国际财务报告准则》下归属于本公司股东 的净利润（以下简称"经调整归母净利润"）约人民币 1,495,655 万元，同比增 长约 41.33%。 3、公司预计本期实现归属于本公司股东的扣除非经常性损益的净利润约人 民币 1,3 ...

针对业绩预增的原因，药明康德表示，公司持续聚焦独特的"一体化、端到端"CRDMO（合同研究、开 发与生产）业务模式，紧抓客户对赋能需求的确定性，不断拓展新能力、建设新产能，持续优化生产工 艺和提高经营效率，推动业务持续稳健增长，高效极致赋能客户并致力于将更多新药、好药带给全球病 患。 北京商报讯（记者 丁宁）1月12日晚间，药明康德（603259）发布2025年度业绩预增公告显示，公司预 计2025年度实现营业收入约454.56亿元，同比增长约15.84%，其中持续经营业务收入同比增长约 21.4%。公司预计本期实现归属净利润约191.51亿元，同比增长约102.65%，其中包含了出售联营公司部 分股权以及剥离部分业务所获得的投资收益。 此外，本期非经常性损益项目对归属净利润的影响主要来自于出售持有的WuXi XDC Cayman Inc.部分 股权的净收益，预计约41.61亿元；以及出售所持有的上海康德弘翼医学临床研究有限公司和上海药明 津石医药科技有限公司100%股权的净收益，预计约14.34亿元。 ...

Core Viewpoint - WuXi AppTec (603259.SH) expects significant revenue and profit growth for the fiscal year 2025, driven by its integrated CRDMO business model and increasing client demand for enabling services [1] Financial Performance - The company anticipates a revenue of approximately RMB 45.456 billion, representing a year-on-year increase of about 15.84% [1] - Expected revenue from continuing operations is projected to grow by approximately 21.40% [1] - Adjusted net profit attributable to shareholders is estimated at around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be about RMB 13.241 billion, with a year-on-year increase of approximately 32.56% [1] - Total net profit is projected to reach approximately RMB 19.151 billion, marking a year-on-year growth of about 102.65% [1] - Total profit is expected to be around RMB 23.906 billion, indicating a year-on-year increase of approximately 107.16% [1] - Basic earnings per share are anticipated to be approximately RMB 6.70, reflecting a year-on-year growth of about 104.27% [1] Business Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, aiming to meet the growing client demand for enabling services [1] - WuXi AppTec is committed to expanding new capabilities, building new production capacity, and continuously optimizing production processes to enhance operational efficiency [1] - The company aims to drive steady business growth while efficiently empowering clients and delivering more new and effective drugs to global patients [1]

WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 正面盈利預告 本公告乃由本公司根據上海證券交易所股票上市規則的規定及香港聯合交易 所有限公司證券上市規則第13.09(2)(a)條及香港法例第571章《證券及期貨條例》 第XIVA部有關披露義務的規定，在上海證券交易所及香港聯合交易所有限 公司同步刊登。董事會謹此公告，預期本公司於截至2025年12月31日止年度 營業收入及歸屬於本公司股東的淨利潤相比2024年年度同期將錄得上升。 股東及有意投資者在買賣本公司證券時務須謹慎行事。 本公告乃由無錫藥明康德新藥開發股份有限公司（「本公司」或「公司」）根據上 海證券交易所股票上市規則的規定及香港聯合交易所有限公司證券上市規則 第13.09(2)(a)條及香港法例第571章《證券及期貨條例》第XIVA部有關披露義務 ...